Wolfe Research analyst Nigel Coe downgrades Regal Rexnord (NYSE:RRX) from Outperform to Peer Perform.
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
Replimune reported that the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma showed a 33.6% response rate, with all responses lasting over six months. The treatment was well-tolerated.
